ArticleBriefings in bioinformatics2026
GFSeeker: a splicing-graph-based approach for accurate gene fusion detection from long-read RNA sequencing data.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Benchmarking genomic foundation models for binary classification of gene fusion breakpoints from DNA sequences.BioData mining · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gene fusions are critical oncogenic drivers and therapeutic targets in diverse cancers. Long-read ribonucleic acid sequencing (RNA-seq) offers an unprecedented opportunity to resolve the full-length structure of fusion isoforms, but its high intrinsic error rates pose significant challenges to the precise identification of true fusion events. Here, we developed GFSeeker, an innovative splicing-graph-based computational framework for accurate gene fusion detection from long-read RNA-seq. GFSeeker employs a unique pipeline based on a splicing graph reference and a dual re-alignment validation to effectively overcome data noise from high error rates. Benchmarking across simulated, non-tumor, and cancer cell line datasets demonstrated GFSeeker's state-of-the-art performance, achieving 6%-15% higher F1 score compared to existing methods. Notably, GFSeeker successfully identified the known fusion event, MATN2-POP1, in the MCF-7 cancer cell line, missed by other tools, highlighting its superior sensitivity in resolving complex fusion events. These results validate GFSeeker as a powerful and reliable tool for gene fusion discovery, heralding its significant potential to advance cancer research and precision diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.